Search research articles
Contact Us
Filters
Showing results (111-120 of 121) with videos related to
Page
of 13
Sort By:
Elife
|
July 26, 2024
SPAG7 deletion causes intrauterine growth restriction, resulting in adulthood obesity and metabolic dysfunction
Stephen E Flaherty, Olivier Bezy, Brianna LaCarubba Paulhus, et al.
Translational Psychiatry
|
October 21, 2015
Increased abundance of translation machinery in stem cell-derived neural progenitor cells from four schizophrenia patients
A Topol, J A English, E Flaherty, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 25, 2005
ACCO: ASCO core curriculum outline
Hyman B Muss, Jamie Von Roenn, Lloyd Earl Damon, et al.
JNCI Cancer Spectrum
|
March 15, 2026
Long-Term follow-up of S0221, comparing alternative Dose-Schedules of anthracycline/taxane therapy in early breast cancer
Azka Ali, William E Barlow, Halle C F Moore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 31, 2004
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma
David F McDermott, Meredith M Regan, Joseph I Clark, et al.
Nature Communications
|
July 4, 2023
Chronic UCN2 treatment desensitizes CRHR2 and improves insulin sensitivity
Stephen E Flaherty, Olivier Bezy, Wei Zheng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 26, 2014
SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer
George T Budd, William E Barlow, Halle C F Moore, et al.
Journal for Immunotherapy of Cancer
|
May 8, 2021
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
Ahmad A Tarhini, Ni Kang, Sandra J Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 31, 2017
Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697)
Sanjiv S Agarwala, Sandra J Lee, Waiki Yip, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 28, 2019
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609
Ahmad A Tarhini, Sandra J Lee, F Stephen Hodi, et al.
Page
of 13
Search research articles
Search
Showing results (111-120 of 121) with videos related to
Sort By:
Page
of 13
Elife
|
July 26, 2024
SPAG7 deletion causes intrauterine growth restriction, resulting in adulthood obesity and metabolic dysfunction
Stephen E Flaherty, Olivier Bezy, Brianna LaCarubba Paulhus, et al.
Translational Psychiatry
|
October 21, 2015
Increased abundance of translation machinery in stem cell-derived neural progenitor cells from four schizophrenia patients
A Topol, J A English, E Flaherty, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 25, 2005
ACCO: ASCO core curriculum outline
Hyman B Muss, Jamie Von Roenn, Lloyd Earl Damon, et al.
JNCI Cancer Spectrum
|
March 15, 2026
Long-Term follow-up of S0221, comparing alternative Dose-Schedules of anthracycline/taxane therapy in early breast cancer
Azka Ali, William E Barlow, Halle C F Moore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 31, 2004
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma
David F McDermott, Meredith M Regan, Joseph I Clark, et al.
Nature Communications
|
July 4, 2023
Chronic UCN2 treatment desensitizes CRHR2 and improves insulin sensitivity
Stephen E Flaherty, Olivier Bezy, Wei Zheng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 26, 2014
SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer
George T Budd, William E Barlow, Halle C F Moore, et al.
Journal for Immunotherapy of Cancer
|
May 8, 2021
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
Ahmad A Tarhini, Ni Kang, Sandra J Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 31, 2017
Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697)
Sanjiv S Agarwala, Sandra J Lee, Waiki Yip, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 28, 2019
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609
Ahmad A Tarhini, Sandra J Lee, F Stephen Hodi, et al.
Page
of 13